August 14, 2025 — Werewolf Therapeutics, Inc. (Nasdaq: HOWL) provided a business update and reported financial results for the second quarter ended June 30, 2025. The company’s WTX-124 Phase 1/1b clinical trial is on track for interim data in Q4 2025, with patients in monotherapy and combination expansion arms of cutaneous melanoma and renal cell carcinoma.
The company plans to engage with the FDA in the second half of 2025 to discuss potential registrational pathways for WTX-124 in advanced or metastatic cutaneous melanoma. The Phase 1b/2 clinical trial of WTX-330 is actively enrolling, with an anticipated dosing regimen determination by the end of 2025. Werewolf announced WTX-1011, its first INDUCER™ T-cell engager development candidate, targeting STEAP1.
As of June 30, 2025, cash and cash equivalents were $77.6 million. The company believes its existing cash will fund operational expenses and capital expenditure requirements into the fourth quarter of 2026.
Research and development expenses were $13.1 million for the second quarter of 2025, and general and administrative expenses were $4.4 million. Net loss was $18.0 million for the second quarter of 2025.
Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, stated that the company continues to advance its PREDATOR® platform and capitalize on clinical data from its lead INDUKINE™ asset, WTX-124.
Contact:
Dan Ferry
LifeSci Advisors
617.430.7576
daniel@lifesciadvisors.com
Amanda Sellers
Deerfield Group
301.332.5574
amanda.sellers@deerfieldgroup.com
Tim Trost
Chief Financial Officer
Werewolf Therapeutics
ttrost@werewolftx.com
